{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:48:28Z","timestamp":1787532508780,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007890","name":"University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["T32CA116339"],"award-info":[{"award-number":["T32CA116339"]}],"id":[{"id":"10.13039\/100007890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U58DP003862-01"],"award-info":[{"award-number":["U58DP003862-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011082","name":"School of Medicine, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013218","name":"Center for Ecological Research, Kyoto University","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/501100013218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005002","name":"California Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jgo.2023.101602","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T12:16:42Z","timestamp":1694261802000},"page":"101602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort study"],"prefix":"10.1016","volume":"14","author":[{"given":"Emilie D.","family":"Duchesneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"McNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Schary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jgo.2023.101602_bb0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jgo.2023.101602_bb0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) task force","volume":"28","author":"Stauder","year":"2017","journal-title":"Ann Oncol"},{"issue":"10129","key":"10.1016\/j.jgo.2023.101602_bb0015","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.jgo.2023.101602_bb0020","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.jgo.2023.101602_bb0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-016-0257-2","article-title":"Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century","volume":"9","author":"Pulte","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2023.101602_bb0030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ejh.12468","article-title":"Survival for patients with chronic leukemias in the US and Britain: age-related disparities and changes in the early 21st century","volume":"94","author":"Pulte","year":"2015","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.jgo.2023.101602_bb0035","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.3324\/haematol.2017.185868","article-title":"Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.jgo.2023.101602_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.beha.2017.10.007","article-title":"What is the optimal management of older CLL patients?","volume":"31","author":"Woyach","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.jgo.2023.101602_bb0045","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2023.101602_bb0050","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 1.2022 - September 8, 2021","author":"National Comprehensive Cancer Network","year":"2021"},{"key":"10.1016\/j.jgo.2023.101602_bb0055","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 3.2022 \u2013 June 3","author":"National Comprehensive Cancer Network","year":"2022"},{"issue":"9747","key":"10.1016\/j.jgo.2023.101602_bb0060","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.jgo.2023.101602_bb0065","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2023.101602_bb0070","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/j.clml.2020.02.013","article-title":"Novel targeted therapies for chronic lymphocytic leukemia in elderly patients: a systematic review","volume":"20","author":"Farooqui","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jgo.2023.101602_bb0075","author":"National Cancer Institute"},{"key":"10.1016\/j.jgo.2023.101602_bb0080","author":"National Cancer Institute"},{"key":"10.1016\/j.jgo.2023.101602_bb0085","series-title":"NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 1.2020","author":"National Comprehensive Cancer Network","year":"2019"},{"issue":"6","key":"10.1016\/j.jgo.2023.101602_bb0090","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M18-3079","article-title":"Graphical depiction of longitudinal study designs in health care databases","volume":"170","author":"Schneeweiss","year":"2019","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jgo.2023.101602_bb0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"13","key":"10.1016\/j.jgo.2023.101602_bb0100","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood-2010-08-301929","article-title":"An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia","volume":"117","author":"Danese","year":"2011","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.jgo.2023.101602_bb0105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol"},{"issue":"3","key":"10.1016\/j.jgo.2023.101602_bb0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/aje\/kws580","article-title":"Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence","volume":"178","author":"Cho","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.jgo.2023.101602_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pds.3719","article-title":"Using claims data to predict dependency in activities of daily living as a proxy for frailty","volume":"24","author":"Faurot","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.jgo.2023.101602_bb0120","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/EDE.0000000000000833","article-title":"Controlling for frailty in Pharmacoepidemiologic studies of older adults: validation of an existing Medicare claims-based algorithm","volume":"29","author":"Cuthbertson","year":"2018","journal-title":"Epidemiology."},{"issue":"5","key":"10.1016\/j.jgo.2023.101602_bb0125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jgo.2023.101602_bb0130","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Stat"},{"issue":"496\u2013509","key":"10.1016\/j.jgo.2023.101602_bb0135","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.jgo.2023.101602_bb0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgo.2013.01.002","article-title":"First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis","volume":"4","author":"Michallet","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2023.101602_bb0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.jgo.2023.101602_bb0150","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.jgo.2023.101602_bb0155","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and Management of Vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2023.101602_bb0160","first-page":"78","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.jgo.2023.101602_bb0165","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia."},{"issue":"11","key":"10.1016\/j.jgo.2023.101602_bb0170","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jgo.2023.101602_bb0175","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"O\u2019Brien","year":"2015","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.jgo.2023.101602_bb0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.jgo.2023.101602_bb0185","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jgo.2023.101602_bb0190","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.3324\/haematol.2015.132035","article-title":"A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients","volume":"100","author":"Tedeschi","year":"2015","journal-title":"Haematologica."},{"issue":"23","key":"10.1016\/j.jgo.2023.101602_bb0195","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jgo.2023.101602_bb0200","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jgo.2023.101602_bb0205","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLLIPIwg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2023.101602_bb0210","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00277-014-2048-6","article-title":"Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database","volume":"93","author":"Satram-Hoang","year":"2014","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jgo.2023.101602_bb0215","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4235\/agmr.20.0002","article-title":"Measuring frailty in health care databases for clinical care and research","volume":"24","author":"Kim","year":"2020","journal-title":"Ann Geriatr Med Res"},{"issue":"2","key":"10.1016\/j.jgo.2023.101602_bb0220","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jgo.2012.12.005","article-title":"A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes","volume":"4","author":"Davidoff","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2023.101602_bb0225","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","article-title":"Development of a claims-based frailty indicator anchored to a well-established frailty phenotype","volume":"55","author":"Segal","year":"2017","journal-title":"Med Care"},{"issue":"7","key":"10.1016\/j.jgo.2023.101602_bb0230","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"8","key":"10.1016\/j.jgo.2023.101602_bb0235","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/gerona\/gly197","article-title":"Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study","volume":"74","author":"Kim","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"10.1016\/j.jgo.2023.101602_bb0240","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/aje\/kwx257","article-title":"External validation of the claims-based frailty index in the national health and aging trends study cohort","volume":"186","author":"Segal","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.jgo.2023.101602_bb0245","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"10.1016\/j.jgo.2023.101602_bb0250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jgo.2023.101602_bb0255","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MLR.0000000000001073","article-title":"Comparison of Medicare claims-based proxy measures of poor function and associations with treatment receipt and mortality in older Colon Cancer patients","volume":"57","author":"Mayer","year":"2019","journal-title":"Med Care"},{"issue":"20","key":"10.1016\/j.jgo.2023.101602_bb0260","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/jnci\/djq366","article-title":"Improved estimates of cancer-specific survival rates from population-based data","volume":"102","author":"Howlader","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"4 Suppl","key":"10.1016\/j.jgo.2023.101602_bb0265","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/107327481502204s04","article-title":"Management of chronic lymphocytic leukemia in the elderly","volume":"22","author":"Barrientos","year":"2015","journal-title":"Cancer Control"},{"issue":"10232","key":"10.1016\/j.jgo.2023.101602_bb0270","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.jgo.2023.101602_bb0275","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2023.03.013","article-title":"Defining the role of real-world data in cancer clinical research: the position of the European Organisation for Research and Treatment of Cancer","volume":"186","author":"Saesen","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823001996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823001996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:57:33Z","timestamp":1761818253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406823001996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1879406823001996"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101602","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101602"}}